Physician profile
Charles E Hall
NPI 1598973471
$10,274.87
in general payments reported to CMS, 2019-2025
34 companies · $2,843 in 2025
The $2,843 reported for 2025 was more than what 96% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $427 · 2021: $782 · 2022: $1,368 · 2023: $1,911 · 2024: $2,149 · 2025: $2,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,467 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,466.97 |
| Education | $436.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,083.65 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $903.02 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $761.15 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $715.68 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $563.18 | 2019-2025 | Spravato, Invega |
| Ironshore Pharmaceuticals INC. | $558.23 | 2019-2024 | Jornay Pm |
| Corium, LLC | $490.96 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $451.90 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $432.94 | 2019-2025 | Trintellix |
| National Marrow Donor Program | $403.68 | 2025 | |
| Sunovion Pharmaceuticals INC. | $397.17 | 2019-2022 | |
| Lundbeck LLC | $384.09 | 2019-2025 | Rexulti |
| Alkermes, INC. | $367.62 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $317.05 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $290.69 | 2023-2025 | Auvelity, Sunosi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $277.21 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Almatica Pharma LLC | $245.55 | 2022-2025 | Loreev Xr, Gralise |
| Collegium Pharmaceutical, INC. | $242.40 | 2025 | Jornay Pm |
| Tris Pharma INC | $207.67 | 2019-2025 | Dyanavel Xr |
| Kite Pharma, INC. | $198.97 | 2024-2025 | Yescarta |
| Abbvie INC. | $182.70 | 2023-2024 | |
| Neos Therapeutics, Lp | $139.64 | 2019-2025 | Adzenys Xr-Odt |
| Seagen INC. | $114.17 | 2020 | |
| Neuronetics, INC. | $92.21 | 2024-2025 | Neurostar Tms Therapy System |
| Noven Therapeutics, LLC | $85.35 | 2022-2024 | Secuado, Xelstrym |
| Shire North American Group INC | $80.79 | 2019 | |
| Bausch Health US, LLC | $54.24 | 2022 | |
| Harmony Biosciences LLC | $47.61 | 2025 | |
| Vertical Pharmaceuticals, LLC | $47.42 | 2019-2020 | |
| Tms Neurohealth Centers INC. | $36.65 | 2025 | Tms Neurohealth Centers INC. |
| Eisai INC. | $32.60 | 2021-2022 | |
| Adlon Therapeutics L.P. | $29.15 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.82 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.